Outsourcing and trial management tool puts professionals in control of all aspects of a study
Outsourcing and trial management tool puts professionals in control of all aspects of a study
EquaTerra (Houston, TX) released an outsourcing and business process management and governance solution based on Microsoft business intelligence technology. Designed to help manage the complexity of blended outsourcing, offshoring, and internal shared services, the comprehensive governance tool provides an enterprise-wide view, enabling plug-ins for other business process intelligence and outsourcing management tools.
The Business Services Dashboard helps organizations derive all the possible value from their business process transformation initiatives. The dashboard solution allows users to view the current status of each business process, along with measurement and management of provider performance. The new product provides drill-down details in six critical business process governance areas: financial management, issue management, contract management, performance management, compliance management, and relationship management.
EquaTerra, (713) 669-9292, www.equaterra.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.